.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,780,485

« Back to Dashboard

Summary for Patent: 5,780,485

Title: Use of .alpha..sub.1c specific compounds to treat benign prostatic hyperplasia
Abstract:A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
Inventor(s): Gluchowski; Charles (Wayne, NJ), Forray; Carlos C. (Waldwick, NJ), Chiu; George (Bridgewater, NJ), Branchek; Theresa A. (Teaneck, NJ), Wetzel; John M. (Elmwood Park, NJ), Hartig; Paul R. (Princeton, NJ)
Assignee: Synaptic Pharmaceutical Corporation (Paramus, NJ)
Application Number:08/415,681
Patent Claim Types:
see list of patent claims
Use;
Patent PDF download available with subscription

No matches for this query

International Patent Family for Patent: 5,780,485

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia680457<disabled in preview>
Australia700304<disabled in preview>
Australia2240495<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc